Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02413749 · ClinicalTrials.gov registry record
DC-STAMP & TRAF3: Regulators of Osteoclastogenesis and Biomarkers in PsA
A clinical trial of Psoriatic Arthritis, sponsored by University of Rochester.
- Completed
- Registry status
- 68
- Enrollment target
- 1
- Study location
NCT02413749 is a study of Psoriatic Arthritis that has completed, run by University of Rochester. The registered enrollment target is 68 participants, below the 851-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02413749, a study of Psoriatic Arthritis, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- 68 participants
- Enrollment target
- 1
- Study location
Study Summary
Biologics such as anti-Tumor Necrosis Factor or TNF inhibitor (TNFi) for treatment of Psoriatic Arthritis (PsA) has greatly reduced bone damage. This collaborative study will provide insights into key mechanisms that underlie inflammatory arthritis and bone damage in psoriatic joints and will catalyze biomarker discovery, identifying early biologic responders to facilitate optimization of therapy.
Conditions Studied
Study Locations (1)
New York
- University of Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2015-04-13 |
| Est. Completion | 2016-12-28 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02413749
The ClinicalTrials.gov registry entry for NCT02413749 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 851-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (92% lower). The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psoriatic Arthritis appearing as the primary indexed condition, and to 0 interventions.
NCT02413749 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT02413749 about?
NCT02413749 is a clinical study titled "DC-STAMP & TRAF3: Regulators of Osteoclastogenesis and Biomarkers in PsA". Biologics such as anti-Tumor Necrosis Factor or TNF inhibitor (TNFi) for treatment of Psoriatic Arthritis (PsA) has greatly reduced bone damage. This collaborative study will provide insights into key mechanisms that underlie inflammatory arthritis and bone damage in psoriatic joints and will cataly...
What is the current status of trial NCT02413749?
This trial is currently completed. The enrollment target is 68 participants. The study started on 2015-04-13. Estimated completion is 2016-12-28.
What conditions does trial NCT02413749 study?
This clinical trial studies the following conditions: Psoriatic Arthritis.
Who is sponsoring clinical trial NCT02413749?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02413749 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriatic Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
RECRUITING
-
Rheumatology Diet Study
RECRUITING
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Stronger Together Psoriatic Arthritis Wellness Study
RECRUITING
-
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
RECRUITING · Phase 1
-
Creating Health Course Study for People With Rheumatological Conditions
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.